<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072877</url>
  </required_header>
  <id_info>
    <org_study_id>VAP.VV015</org_study_id>
    <nct_id>NCT01072877</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence</brief_title>
  <acronym>VANISH-1</acronym>
  <official_title>A Randomized, Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Polidocanol Injectable Foam 0.5%, 1.0%, or 2.0% Compared to Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BTG International Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BTG International Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Varicose veins are enlarged, noticeably bulging veins, which commonly occur in the legs and
      may cause discomfort. In this study, patients with varicose veins in the legs will be
      participating. The purpose of this research study is to evaluate the safety and effectiveness
      of three different concentrations of an investigational drug, polidocanol injectable foam
      compared to vehicle (inactive solution) in treating the symptoms and appearance of varicose
      veins.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score)</measure>
    <time_frame>Week 8</time_frame>
    <description>The 9 varicose vein symptoms were to be assessed and graded on a 6-point (i.e., 0-5) duration scale and an 11-point (i.e., 0-10) intensity scale, and the patient's level of activity for that day was to be assessed and graded on the 6-point (i.e., 0-5) duration scale. The 9 varicose vein symptoms assessed using the e-diary were derived from the first question of the modified Venous Insufficiency Epidemiologic and Economic Study-Quality of Life/Symptoms (VEINES-QOL/Sym) instrument. The VVSymQ is a subset of 5 VEINESQOL/ Sym items that have been determined in earlier studies to be most important to patients (heaviness, achiness, swelling, throbbing, and itching).
The daily VVSymQ score is the sum of the duration scores for these 5 symptoms (scores range from 0 to 25, with the lower end of the range being an indicator of less symptom intensity, and the higher end being an indicator of higher intensity).
At Visit 2/baseline, Week 8, scores were calculated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3)</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this single-item paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from &quot;Not at all noticeable&quot; (a score of 0) to &quot;Extremely noticeable&quot; (a score of 4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline at 8 Weeks Post Treatment in IPR-V3 Score- Physician Photographic Review of Appearance</measure>
    <time_frame>8 weeks post treatment</time_frame>
    <description>The Independent Photography Review - Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient's visible varicose veins. At baseline and Week 8, standardized digital photographs were taken of the medial view of the patient's target leg, from groin to ankle. An independent photography review panel, consisting of 3 trained, blinded clinicians evaluated the appearance of the patient's visible varicose veins using the IPR-V3 instrument's 5-point scale (where 0=none to 4=very severe visible varicose veins).</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">279</enrollment>
  <condition>Varicose Veins</condition>
  <arm_group>
    <arm_group_label>Polidocanol injectable foam 0.125%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polidocanol injectable foam 0.125%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polidocanol injectable foam 0.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polidocanol injectable foam 0.5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polidocanol injectable foam 1.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polidocanol injectable foam 1.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Polidocanol injectable foam 2.0%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polidocanol injectable foam 2.0%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of vehicle comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polidocanol injectable foam (PEM)</intervention_name>
    <description>Injection of Polidocanol injectable foam</description>
    <arm_group_label>Polidocanol injectable foam 0.125%</arm_group_label>
    <arm_group_label>Polidocanol injectable foam 0.5%</arm_group_label>
    <arm_group_label>Polidocanol injectable foam 1.0%</arm_group_label>
    <arm_group_label>Polidocanol injectable foam 2.0%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Vehicle</intervention_name>
    <description>Placebo vehicle</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Incompetence of SFJ associated with incompetence of the GSV or other major accessory
             vein

          -  Ability to comprehend and sign an informed consent document and complete study
             questionnaires in English

          -  Ability to record symptoms in accordance with the protocol

          -  Symptomatic varicose veins

          -  Visible varicose veins

        Exclusion Criteria:

          -  Patients who only have telangiectatic or reticular veins (Clinical Finding C1, as
             assessed by CEAP (clinical, etiologic, anatomic, and pathophysiologic) Classification
             of Venous Disorders).

          -  Leg obesity impairing the ability to access the vein to be treated and/or to apply
             postprocedure compression bandaging and stockings

          -  Ultrasonographic or other evidence of current or previous deep vein thrombosis or
             occlusion

          -  Deep vein reflux unless clinically insignificant in comparison to superficial reflux

          -  Peripheral arterial disease precluding the wearing of post-procedure compression
             bandaging and stockings

          -  Reduced mobility

          -  Major surgery, prolonged hospitalization or pregnancy within 3 months of screening

          -  Major co-existing disease (e.g. malignancy; pulmonary disease; renal or hepatic
             insufficiency; serious skin disease/condition that may compromise the ability of the
             patient to comply with the compression protocol, etc.)

          -  Known allergic response to polidocanol or heparin, including history of
             heparin-induced thrombocytopenia, and/or multiple allergic reactions

          -  Current alcohol or drug abuse

          -  Pregnant or lactating women

          -  Women of childbearing potential not using effective contraception

          -  History of DVT, pulmonary embolism or stroke
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartsdale</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Towanda</city>
        <state>New York</state>
        <zip>14120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <zip>10530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <zip>97701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarksville</city>
        <state>Tennessee</state>
        <zip>37040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kirkland</city>
        <state>Washington</state>
        <zip>98034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2010</study_first_submitted>
  <study_first_submitted_qc>February 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2010</study_first_posted>
  <results_first_submitted>January 15, 2014</results_first_submitted>
  <results_first_submitted_qc>April 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2014</results_first_posted>
  <disposition_first_submitted>July 23, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">January 9, 2014</disposition_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Varicose Veins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polidocanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vehicle</title>
          <description>Injection of vehicle comparator
Placebo Vehicle: Placebo vehicle</description>
        </group>
        <group group_id="P2">
          <title>Polidocanol Endovenous Microfoam 0.125%</title>
          <description>Polidocanol endovenous microfoam 0.125%
Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam</description>
        </group>
        <group group_id="P3">
          <title>Polidocanol Endovenous Microfoam 0.5%</title>
          <description>Polidocanol endovenous microfoam 0.5%
Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam</description>
        </group>
        <group group_id="P4">
          <title>Polidocanol Endovenous Microfoam 1.0%</title>
          <description>Polidocanol endovenous microfoam 1.0%
Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam</description>
        </group>
        <group group_id="P5">
          <title>Polidocanol Endovenous Microfoam 2.0%</title>
          <description>Polidocanol endovenous microfoam 2.0%
Polidocanol Endovenous Microfoam (PEM): Injection of Polidocanol Endovenous Microfoam</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="57"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="52"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="51"/>
                <participants group_id="P4" count="50"/>
                <participants group_id="P5" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population</population>
      <group_list>
        <group group_id="B1">
          <title>Vehicle</title>
          <description>Injection of vehicle comparator
Placebo Vehicle: Placebo vehicle</description>
        </group>
        <group group_id="B2">
          <title>Polidocanol Injectable Foam 0.125%</title>
          <description>Polidocanol injectable foam 0.125%</description>
        </group>
        <group group_id="B3">
          <title>Polidocanol Injectable Foam 0.5%</title>
          <description>Polidocanol injectable foam 0.5%</description>
        </group>
        <group group_id="B4">
          <title>Polidocanol Injectable Foam 1.0%</title>
          <description>Polidocanol injectable foam 1.0%</description>
        </group>
        <group group_id="B5">
          <title>Polidocanol Injectable Foam 2.0%</title>
          <description>Polidocanol injectable foam2.0%</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="57"/>
            <count group_id="B3" value="51"/>
            <count group_id="B4" value="52"/>
            <count group_id="B5" value="63"/>
            <count group_id="B6" value="279"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.0" spread="11.31"/>
                    <measurement group_id="B2" value="51.6" spread="9.60"/>
                    <measurement group_id="B3" value="48.2" spread="11.78"/>
                    <measurement group_id="B4" value="48.8" spread="8.78"/>
                    <measurement group_id="B5" value="49.7" spread="10.49"/>
                    <measurement group_id="B6" value="48.9" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="37"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B5" value="61"/>
                    <measurement group_id="B6" value="260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.7" spread="5.95"/>
                    <measurement group_id="B2" value="28.8" spread="5.77"/>
                    <measurement group_id="B3" value="27.4" spread="5.75"/>
                    <measurement group_id="B4" value="28.6" spread="5.41"/>
                    <measurement group_id="B5" value="28.3" spread="5.40"/>
                    <measurement group_id="B6" value="28.2" spread="5.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score)</title>
        <description>The 9 varicose vein symptoms were to be assessed and graded on a 6-point (i.e., 0-5) duration scale and an 11-point (i.e., 0-10) intensity scale, and the patient’s level of activity for that day was to be assessed and graded on the 6-point (i.e., 0-5) duration scale. The 9 varicose vein symptoms assessed using the e-diary were derived from the first question of the modified Venous Insufficiency Epidemiologic and Economic Study-Quality of Life/Symptoms (VEINES-QOL/Sym) instrument. The VVSymQ is a subset of 5 VEINESQOL/ Sym items that have been determined in earlier studies to be most important to patients (heaviness, achiness, swelling, throbbing, and itching).
The daily VVSymQ score is the sum of the duration scores for these 5 symptoms (scores range from 0 to 25, with the lower end of the range being an indicator of less symptom intensity, and the higher end being an indicator of higher intensity).
At Visit 2/baseline, Week 8, scores were calculated</description>
        <time_frame>Week 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Injection of vehicle
Placebo Vehicle: Placebo vehicle</description>
          </group>
          <group group_id="O2">
            <title>Polidocanol Injectable Foam 0.125%</title>
            <description>Polidocanol injectable foam at a 0.125% concentration</description>
          </group>
          <group group_id="O3">
            <title>Polidocanol Injectable Foam 0.5%</title>
            <description>polidocanol injectable foam at a 0.5% concentration</description>
          </group>
          <group group_id="O4">
            <title>Polidocanol Injectable Foam 1.0%</title>
            <description>Polidocanol injectable foam at 1.0% concentration</description>
          </group>
          <group group_id="O5">
            <title>Polidocanol Injectable Foam 2.0%</title>
            <description>Polidocanol injectable foam at a 2.0% concentration</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Patient-reported Symptoms of Varicose Veins (VVSymQ Score)</title>
          <description>The 9 varicose vein symptoms were to be assessed and graded on a 6-point (i.e., 0-5) duration scale and an 11-point (i.e., 0-10) intensity scale, and the patient’s level of activity for that day was to be assessed and graded on the 6-point (i.e., 0-5) duration scale. The 9 varicose vein symptoms assessed using the e-diary were derived from the first question of the modified Venous Insufficiency Epidemiologic and Economic Study-Quality of Life/Symptoms (VEINES-QOL/Sym) instrument. The VVSymQ is a subset of 5 VEINESQOL/ Sym items that have been determined in earlier studies to be most important to patients (heaviness, achiness, swelling, throbbing, and itching).
The daily VVSymQ score is the sum of the duration scores for these 5 symptoms (scores range from 0 to 25, with the lower end of the range being an indicator of less symptom intensity, and the higher end being an indicator of higher intensity).
At Visit 2/baseline, Week 8, scores were calculated</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" spread="0.452"/>
                    <measurement group_id="O2" value="4.63" spread="0.447"/>
                    <measurement group_id="O3" value="5.68" spread="0.483"/>
                    <measurement group_id="O4" value="4.87" spread="0.477"/>
                    <measurement group_id="O5" value="5.78" spread="0.425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.49</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.72</ci_lower_limit>
            <ci_upper_limit>-1.27</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.80</ci_lower_limit>
            <ci_upper_limit>-2.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.98</ci_lower_limit>
            <ci_upper_limit>-1.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.84</ci_lower_limit>
            <ci_upper_limit>-2.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3)</title>
        <description>The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this single-item paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from “Not at all noticeable” (a score of 0) to “Extremely noticeable” (a score of 4).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Injection of vehicle
Placebo Vehicle: Placebo vehicle</description>
          </group>
          <group group_id="O2">
            <title>Polidocanol Injectable Foam 0.125%</title>
            <description>Polidocanol injectable foam at a 0.125% concentration</description>
          </group>
          <group group_id="O3">
            <title>Polidocanol Injectable Foam 0.5%</title>
            <description>Polidocanol injectable foam at a 0.5% concentration</description>
          </group>
          <group group_id="O4">
            <title>Polidocanol Injectable Foam 1.0%</title>
            <description>Polidocanol injectable foam at a 1.0% concentration</description>
          </group>
          <group group_id="O5">
            <title>Polidocanol Injectable Foam 2.0%</title>
            <description>Polidocanol injectable foam at a 2.0% concentration</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to 8 Weeks in Appearance as Rated by Patient (PA-V3)</title>
          <description>The Patient Self-assessment of Visible Varicose Veins (PA-V3) instrument is a 5-point scale used by patients to evaluate the appearance of their visible varicose veins. On this single-item paper questionnaire, the instructions included a diagram of the medial view of a leg with the area between the ankle and the groin circled. The patient was instructed to choose 1 of 5 response options that best described the appearance of the visible varicose veins of the leg that was treated in the study. The patient was instructed not to consider the appearance of the leg outside the circled area or of any spider veins. Possible responses ranged from “Not at all noticeable” (a score of 0) to “Extremely noticeable” (a score of 4).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="50"/>
                <count group_id="O5" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.143"/>
                    <measurement group_id="O2" value="-0.93" spread="0.142"/>
                    <measurement group_id="O3" value="-1.40" spread="0.152"/>
                    <measurement group_id="O4" value="-1.60" spread="0.151"/>
                    <measurement group_id="O5" value="-1.75" spread="0.135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.17</ci_lower_limit>
            <ci_upper_limit>-0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.26</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.65</ci_lower_limit>
            <ci_upper_limit>-0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.85</ci_lower_limit>
            <ci_upper_limit>-1.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.98</ci_lower_limit>
            <ci_upper_limit>-1.23</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline at 8 Weeks Post Treatment in IPR-V3 Score- Physician Photographic Review of Appearance</title>
        <description>The Independent Photography Review – Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient’s visible varicose veins. At baseline and Week 8, standardized digital photographs were taken of the medial view of the patient's target leg, from groin to ankle. An independent photography review panel, consisting of 3 trained, blinded clinicians evaluated the appearance of the patient's visible varicose veins using the IPR-V3 instrument's 5-point scale (where 0=none to 4=very severe visible varicose veins).</description>
        <time_frame>8 weeks post treatment</time_frame>
        <population>Population consists of all patients who had a baseline and on-treatment assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Vehicle</title>
            <description>Injection of vehicle
Placebo Vehicle: Placebo vehicle</description>
          </group>
          <group group_id="O2">
            <title>Polidocanol Injectable Foam 0.125%</title>
            <description>Polidocanol injectable foam at a 0.125% concentration</description>
          </group>
          <group group_id="O3">
            <title>Polidocanol Injectable Foam 0.5%</title>
            <description>Polidocanol injectable foam at a 0.5% concentration</description>
          </group>
          <group group_id="O4">
            <title>Polidocanol Injectable Foam 1.0%</title>
            <description>Polidocanol injectable foam at a 1.0% concentration</description>
          </group>
          <group group_id="O5">
            <title>Polidocanol Injectable Foam 2.0%</title>
            <description>Polidocanol injectable foam at a 2.0% concentration</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline at 8 Weeks Post Treatment in IPR-V3 Score- Physician Photographic Review of Appearance</title>
          <description>The Independent Photography Review – Visible Varicose Veins (IPR-V3) instrument is a 5-point scale used to assess the appearance of a patient’s visible varicose veins. At baseline and Week 8, standardized digital photographs were taken of the medial view of the patient's target leg, from groin to ankle. An independent photography review panel, consisting of 3 trained, blinded clinicians evaluated the appearance of the patient's visible varicose veins using the IPR-V3 instrument's 5-point scale (where 0=none to 4=very severe visible varicose veins).</description>
          <population>Population consists of all patients who had a baseline and on-treatment assessment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="56"/>
                <count group_id="O3" value="51"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.081"/>
                    <measurement group_id="O2" value="-0.46" spread="0.080"/>
                    <measurement group_id="O3" value="-0.77" spread="0.086"/>
                    <measurement group_id="O4" value="-0.76" spread="0.085"/>
                    <measurement group_id="O5" value="-0.91" spread="0.077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.45</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>-0.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.98</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.97</ci_lower_limit>
            <ci_upper_limit>-0.53</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.11</ci_lower_limit>
            <ci_upper_limit>-0.68</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Vehicle</title>
          <description>Injection of vehicle
Placebo Vehicle: Placebo vehicle</description>
        </group>
        <group group_id="E2">
          <title>Polidocanol Injectable Foam 0.125%</title>
          <description>polidocanol injectable foam at a 0.125% concentration</description>
        </group>
        <group group_id="E3">
          <title>Polidcanol Injectable Foam 0.5%</title>
          <description>polidocanol injectable foam at a 0.5% concentration</description>
        </group>
        <group group_id="E4">
          <title>Polidocanol Injectable Foam 1.0%</title>
          <description>polidocanol injectable foam at a 1.0% concentration</description>
        </group>
        <group group_id="E5">
          <title>Polidocanol Endovenous Microfoam 2.0%</title>
          <description>polidocanol injectable foam at a 2.0% concentration</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="57"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="51"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="52"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="56"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="51"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Infusion site thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="57"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Injection site hematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="51"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="52"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Edema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="51"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>David Wright MB FRCS</name_or_title>
      <organization>BTG International Inc</organization>
      <phone>610-278-1660</phone>
      <email>david.wright@btgplc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

